Operating revenue dropped 45% and net loss widened due to Medicare non-coverage, with US test volumes falling sharply. Cost-saving measures were implemented, and the company is focused on Medicare appeals and product innovation, while APAC volumes grew modestly.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.